Knopp News Archive
Kv7
Knopp Biosciences Receives Rare Pediatric Disease Designation for Kv7 Activator KB-3061 for Treatment of KCNQ2 Epileptic Encephalopathy
KB-3061 Is a Potent Activator of Wild Type KCNQ Channels and Restores Current to KCNQ2 Encephalopathy Variants In Vitro
Discovery and characterization of KB3061: A potent Kv7.2/7.3 ion channel activator for the treatment of KCNQ2 epileptic encephalopathy
Knopp Biosciences Presents Data Further Characterizing Its Lead Kv7.2 Activator Drug Candidate For The Treatment Of Kcnq2 Epileptic Encephalopathy At The AES 2019 Annual Meeting
Knopp Biosciences to Present Data Characterizing Its Potassium Channel Activator Candidate for the Treatment of KCNQ2 Epileptic Encephalopathy at the American Epilepsy Society’s 2019 Annual Meeting
Knopp Biosciences Receives NIH HEAL Grant to Discover and Advance Non-Opioid Treatment for Chronic Pain
Knopp Biosciences Receives Year 4 Renewal of NIH Blueprint Grant Award for Advancing the Kv7 Activator KB-3061 in a Rare Neonatal Epilepsy
Kv7.2/7.3 Activators as Precision Medicines for the Treatment of KCNQ2-EE
Knopp Biosciences Reports Data Demonstrating Restoration of Function by KB-3061 in Cellular Model of Gene Variants Causing KCNQ2 Epileptic Encephalopathy
The re-emergence of Kv7 drug discovery
Knopp Biosciences to Present Data Characterizing its Kv7 Technology Platform’s Potential for Delivering Precision Medicines to Treat Diverse Neurological and Smooth Muscle Diseases
Targeting Kv7.2/7.3 Activators for the Treatment of KCNQ2-NEE
Knopp Biosciences Presents Positive Preclinical Data for Lead Neonatal Epilepsy Drug Candidate at 2019 Antiepileptic Drug and Device Trials XV Conference
Knopp Biosciences to Present Data on its Potassium Channel Activator Program at 2019 Antiepileptic Drug and Device Trials XV Conference
Knopp Biosciences Enters Research Collaboration with Baylor College of Medicine to Develop New Treatments for KCNQ2 Neonatal Encephalopathy
Knopp Biosciences Announces Year 3 Renewal Of NIH Blueprint Grant Award For Advancing KCNQ2 Activators In Rare Neonatal Epilepsy